SHR-A1904 is named as an intervention in 7 current clinical trials in our China and USA registers. 6 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Jiangsu HengRui Medicine Co., Ltd (2). The most-studied condition is Advanced Solid Tumors.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer
NCT06547736 · ClinicalTrials.gov ↗ · Pancreatic Cancer
|
Phase 2 | Recruiting | Fudan University | China |
|
Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
NCT07102901 · ClinicalTrials.gov ↗ · Advanced Gastric Cancer, Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
|
Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | China |
|
A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer
NCT07110571 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal-junction Cancer
|
Phase 2 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | China |
|
A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
NCT07450976 · ClinicalTrials.gov ↗ · Biliary Tract Cancer
|
Phase 2 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | China |
|
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
NCT05277168 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
|
Phase 1/2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | USA |
|
SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor
NCT06350006 · ClinicalTrials.gov ↗ · CLDN18.2-positive Advanced Solid Tumor
|
Phase 1 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | China |
|
A Phase II Clinical Study of SHR-A1904 Monotherapy in Second-Line or Later Treatment of Advanced Neuroendocrine Carcinoma
NCT07520357 · ClinicalTrials.gov ↗ · Advanced Neuroendocrine Carcinoma
|
Phase 2 | Not yet open | Beijing GoBroad Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Jiangsu HengRui Medicine Co., Ltd. | 2 |
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 2 |
| Beijing GoBroad Hospital | 1 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | 1 |
| Fudan University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 6 | 5 |
| Clinical trials in USA | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
7 current trials in our China and USA registers name SHR-A1904 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 6 of the 7 trials are recruiting: 5 with sites in China and 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Jiangsu HengRui Medicine Co., Ltd (2), Suzhou Suncadia Biopharmaceuticals Co., Ltd (2), Beijing GoBroad Hospital (1) and Shanghai Hengrui Pharmaceutical Co., Ltd (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how SHR-A1904 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how SHR-A1904 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists SHR-A1904 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.